South African bio-pharmaceutical firm BIOVAC and the International Vaccine Institute (IVI) in South Korea have signed a licencing and technology transfer agreement for developing and manufacturing an oral cholera vaccine (OCV).
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
South Africa's Biovac in new oral cholera vaccine deal
More than a year after Pfizer and BioNTech brought Biovac into their global vaccine manufacturing network, the South African vaccine producer has made its first batch of the mRNA shot.
Pfizer and BioNTech linked up with The Biovac Institute in July, enlisting the drugmaker to help manufacture their mRNA-based vaccine Comirnaty in South Africa. Under the partnership, Biovac’s Cape Town plant is set to handle fill-finish duties and chip in 100 million finished doses for the African Union each year, Pfizer has said.
A consortium of nine partners will support Biovac’s expansion of its South African manufacturing plant capacity in an effort to boost production of the Pfizer-BioNTech Covid-19 vaccine.
To support South Africa and the African continent increase vaccine manufacturing capacity and reduce reliance on imports, a consortium of nine development and finance institutions have today announced a partnership with Biovac in Cape Town, South Africa to support Biovac’s vaccine manufacturing expansion.
South Africa`s Biovac to start making Pfizer-BioNTech vaccine in H2 2022 - CEO
Biovac Plans to Become a Vaccine Maker for Underserved Africa